EM-CATH is a next level urinary catheter which does not insert bacteria into the sterile parts of urinary tract, intended both for intermittent and indwelling use, and significantly cuts costs
Current Status
EM-CATH received the Written Opinion of the International Searching Authority confirming the novelty, inventive steps and industrial applicability for all 12 claims. Currently EM-CTH is in national phase of the Patent Cooperation Treaty (PCT) procedure in USA, Europe, Canada, Israel, Russia and China. SremCath company was established in June 2019 and exclusive unconditional license was granted for EM-CATH . A 3-D printed prototype was made. The next step will be small scale production of a sterile finished product ready for pre-clinical and clinical trials.
Problem or Opportunity
Catheter-associated urinary tract infections are killing more people than all traffic accidents worldwide! They also generate further medical conditions, as well as economical, financial, psycho-social burden
Solution (product or service)
We have solution to this problem – EM CATH – innovative urinary catheter, which prevents introducing bacteria into the urinary tract, most of which are multi-resistant. EM-CATH aims to reduce complications related to use of urinary catheters by 50%, to save lives and significantly improve quality of life of millions of patients worldwide, to substantially increase the quality of medical treatment, and to reduce costs of treatment of all medical conditions requiring urinary catheterization.
Business model
EM-CATH provides urinary catheterization without infection, with less complications, discomfort, pain and suffering, restores overall functionality and significantly cuts catheterization-related costs.
EM-CATH’s main market is B2B: predominantly health insurance funds (HIFs), also healthcare institutions (HCs), home and community care (assisted living, rehabilitation).
Main users are elderly – rapidly growing segment.
Most important activities include development, regulatory, marketing and sales.
Main sales channel is direct sales to HIFs and HCs and indirect sales through distributors.
Incubation/Acceleration programs accomplishment
EM-CATH participated at ImagineIF accelerator programme.
SremCath also participated in ImpactHub Serbia accelerator general training programme.
EM-CATH won national contest and second place on the global ImagineIF contest in Cambridge, June 2019
